Is MBRX or MCRB more undervalued in 2026?

CirclFi compares Moleculin Biotech, Inc. (MBRX) and Seres Therapeutics, Inc. (MCRB) using 13 institutional-grade valuation models. MBRX has a Quality of Company score of 4.3/10 while MCRB scores 4.1/10.

Which is a better buy — MBRX or MCRB?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MBRX and MCRB valuations compare?

MBRX at $2.74 and MCRB at $7.58 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MBRX vs MCRB Valuation Comparison 2026 — Intrinsic Value Analysis

MBRX

Biotechnology

Moleculin Biotech, Inc.

Quality

4.3

out of 10

Value Trap

SAFE

Price

$2.74

Last close

Models

7/13

Active

MCRB

Biotechnology

Seres Therapeutics, Inc.

Quality

4.1

out of 10

Value Trap

LOW

Price

$7.58

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	MBRX Fair Value	MBRX Upside	MCRB Fair Value	MCRB Upside
Bayesian DCF	Intrinsic	$1.77	-35.5%	$6.84	-10.2%
Earnings Power Value	Intrinsic	—	—	$19.99	+162.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$7.87	+187.3%	$4.28	-43.8%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MBRX vs MCRB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MBRX vs MCRB — Which Stock Is More Undervalued?

MBRX scores higher with a 4.3/10 quality rating vs MCRB's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Moleculin Biotech, Inc. (MBRX) and Seres Therapeutics, Inc. (MCRB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MBRX currently trades at $2.74 with a QOC of 4.3/10, while MCRB trades at $7.58 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).